You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(6185.HK)午後一度漲超5% 重組新型冠狀病毒疫苗獲國家藥監局受理
格隆匯 02-24 13:59
格隆匯2月24日丨康希諾生物-B(6185.HK)午後拉昇,一度漲超5%至390.8港元,振幅達12.69%。康希諾今日午間宣佈,公司與軍事科學院軍事醫學研究院生物工程研究所共同開發的重組新型冠狀病毒疫苗(5型腺病毒載體)(“Ad5-nCoV”,商品名為克威莎™),在巴基斯坦、墨西哥、俄羅斯、智利及阿根廷5個國家開展了全球多中心Ⅲ期臨牀研究,已完成4萬餘受試者的接種及期中數據分析。2021年2月21日,公司已正式向國家藥監局提交附條件上市申請,並獲得受理。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account